New Combination Treatment Approved for Non-Small Cell Lung Cancer

2018-12-07T14:39:55+00:00December 7th, 2018|Hot Topics, News|0 Comments

The Food and Drug Administration (FDA) approved atezolizumab (TECENTRIQ®), an immunotherapy drug, in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations.

This is the first four drug combination treatment approved for lung cancer.

Click here to learn more.

Leave A Comment